KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Intangibles (2018 - 2025)

Jazz Pharmaceuticals has reported Change in Intangibles over the past 9 years, most recently at $53.5 million for Q4 2025.

  • Quarterly results put Change in Intangibles at $53.5 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $108.5 million (changed N/A YoY), and the annual figure for FY2025 was $108.5 million, changed.
  • Change in Intangibles for Q4 2025 was $53.5 million at Jazz Pharmaceuticals, up from $30.0 million in the prior quarter.
  • Over the last five years, Change in Intangibles for JAZZ hit a ceiling of $53.5 million in Q4 2025 and a floor of $17.9 million in Q3 2021.
  • Median Change in Intangibles over the past 3 years was $25.0 million (2022), compared with a mean of $30.3 million.